Assure Tech Hangzhou Co Ltd - Asset Resilience Ratio
Assure Tech Hangzhou Co Ltd (688075) has an Asset Resilience Ratio of 22.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Assure Tech Hangzhou Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Assure Tech Hangzhou Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Assure Tech Hangzhou Co Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Assure Tech Hangzhou Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Assure Tech Hangzhou Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.27 Billion | 22.07% |
| Total Liquid Assets | CN¥1.27 Billion | 22.07% |
Asset Resilience Insights
- Good Liquidity Position: Assure Tech Hangzhou Co Ltd maintains a healthy 22.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Assure Tech Hangzhou Co Ltd Industry Peers by Asset Resilience Ratio
Compare Assure Tech Hangzhou Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Celldex Therapeutics Inc
NASDAQ:CLDX |
Biotechnology | 81.32% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Assure Tech Hangzhou Co Ltd (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Assure Tech Hangzhou Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.10% | CN¥1.31 Billion ≈ $191.87 Million |
CN¥5.68 Billion ≈ $830.66 Million |
-3.53pp |
| 2024-12-31 | 26.62% | CN¥1.54 Billion ≈ $224.77 Million |
CN¥5.77 Billion ≈ $844.23 Million |
-3.57pp |
| 2023-12-31 | 30.19% | CN¥1.75 Billion ≈ $255.80 Million |
CN¥5.79 Billion ≈ $847.19 Million |
+9.94pp |
| 2022-12-31 | 20.25% | CN¥1.41 Billion ≈ $205.74 Million |
CN¥6.94 Billion ≈ $1.02 Billion |
+20.25pp |
| 2021-12-31 | 0.00% | CN¥144.87K ≈ $21.20K |
CN¥3.28 Billion ≈ $480.03 Million |
-- |
About Assure Tech Hangzhou Co Ltd
Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China and internationally. The company is involved in POCT and plastic product manufacturing; online sales; pharmaceutical manufacturing and sales; and medical testing. It also offers drug of abuse, infectious disease, fertility, cardiac marker, tumor mar… Read more